Immunotherapy, also known as biologic therapy, is a form of cancer treatment that increases the body's natural defenses to fight cancer. Cancer immunotherapy (CI) is the "fifth pillar" of cancer treatment, joining radiation, cytotoxic chemotherapy, surgery, and targeted therapy. Lymphocyte Activation Gene 3 (LAG 3) or CD223 is a gene that codes for a protein that is involved in immune system regulation. It is highly expressed in a variety of tumor-infiltrating lymphocytes (TILs) and has a role in tumor immune escape. It can be employed as a prognostic indication for tumors as well as a target for tumor treatment.
Preclinical research suggests that inhibiting LAG 3 may restore the effector activity of exhausted T lymphocytes and perhaps stimulate an anti-tumor response. Early research suggests that targeting LAG 3 in conjunction with other potentially complementing immunological checkpoints might be a major strategy for more effectively potentiating anti-tumor immune action. The rapid emergence of immuno-oncology (I-O) therapies such as LAG 3 Immunotherapy for numerous tumor types has altered the cancer treatment landscape and improved the long-term outlook for many patients with advanced cancer.
According to DelveInsight's analysis, the market is expected to show positive growth in the coming years due to the launch of potential upcoming therapies in the target LAG 3 Immunotherapy, and the LAG 3 Immunotherapy market size in the 7MM countries is expected to increase and rise up to approximately 7 Billion USD with a significant CAGR by 2035. Furthermore, the United States will have the largest market share of the overall LAG 3 Immunotherapy market in 2035. The growth in the size of the LAG 3 Immunotherapy market is a direct result of the rising incidence population of LAG 3 Next-generation Immunotherapies patients in the 7MM, as well as the anticipated entry of premium-priced target-based drugs, which will have a substantial influence on the LAG 3 Immunotherapy market.
Currently, multiple trials that target LAG 3 Immunotherapy are being conducted for various purposes. Breast Cancer, NSCLC, Gastric Cancer, Gastroesophageal Junction Cancer, Melanoma, Colorectal Cancer, Head and Neck Cancer, and Multiple Myeloma are among the primary indications that are expected to benefit from the implementation of novel drugs.
MacroGenics, Zai Lab, Novartis, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Regeneron, Xencor, F-star Therapeutics, Merck Sharp & Dohme, Crescendo Biologics, MICROBIO Group, Symphogen, Avacta, Abeome Corporation, and other key oncology players are developing novel target LAG 3 Immunotherapies for the treatment of various oncology indication The anticipated launch of new therapies such as MGD013, LAG525, Relatlimab, MK-4280, Eftila Gmod Alpha, REGN3767, XmAb22841, and others will result in a considerable growth in the size of the LAG 3 Immunotherapy market.
Even though the whole biological mechanisms of LAG 3 Immunotherapy is yet to be fully understood, numerous clinical studies are in the early phases of review, followed by preclinical and discovery stages. Many clinical studies are also being evaluated in the middle-to-late stage. Furthermore, the incorporation of new developing technologies for the development of targeted LAG-3 immunotherapy, as well as emerging trends in Next-generation LAG-3 Immunotherapies, are expected to transform cancer treatment in the next few years.
